Q-omics provides the consensus-scored PLAC8 profile across patient tissues and cancer cell-line models. PLAC8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PLAC8 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PLAC8 RNA expression shows 16,333 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, COAD, and UVM as cancer lineages where PLAC8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLAC8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLAC8 survival associations across molecular data types. PLAC8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLAC8 RNA expression–survival associations across cancer types. High PLAC8 expression shows unfavorable associations in LGG and UVM, but favorable associations in BRCA, CESC, SKCM and HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PLAC8 RNA expression.
This table summarizes PLAC8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLAC8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLAC8 shows lower tumor expression in COAD, LUAD, HNSC, LIHC and READ and higher tumor expression in KIRC. The COAD box plot shows higher PLAC8 RNA expression in normal versus tumor tissue (log2 FC = −3.420, t-test p < 0.001).
This table shows molecular features associated with PLAC8 in patient tissues and cancer cell lines. In patient samples, PLAC8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLAC8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
